All In MedTech

FDA Clearance Tracker · P990056-S037

Elecsys total PSA

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 12, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 12, 2020

Approved

Time to decision

180 days

Received Nov 14, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990056-S037
Device name
Elecsys total PSA
Applicant location
Indianapolis, IN
Received
Nov 14, 2019
Decided
May 12, 2020
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P990056

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

Approval for the update of the Elecsys total PSA immunoassay to improve the tolerance to biotin interference.

Source documents

Other decisions for Roche Diagnostics Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.